Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance
Reference number: TA263
Published: 22 August 2012

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): ERG addendum-recalculation of drug costs

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): ERG addendum-recalculation of drug costs

Breast cancer (metastatic) - bevacizumab (1st line, with capecitabine): ERG addendum-recalculation of drug costs
04 July 2012
(312.68 Kb 31 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 04 July 2012